NCT07434401Completed
α-N-acetylgalactosaminidase in Methamphetamine Psychosis
Could α-N-acetylgalactosaminidase Levels Be Associated With the Presence of Psychotic Symptoms in Methamphetamine Use Disorder? A Cross-Sectional Observational Study
Source: ClinicalTrials.gov · Last updated 25 Feb 2026
Brief summary (registry, in English)
This cross-sectional observational cohort study examined serum α-N-acetylgalactosaminidase levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study aimed to determine whether decreased α-N-acetylgalactosaminidase levels are associated with psychotic symptoms in methamphetamine users.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 93 (actual)
- First submitted
- 20 Feb 2026
- Start date
- 1 May 2025
- Primary completion date
- 31 Aug 2025
- Lead sponsor
- Elazığ Mental Health and Diseases Hospital
- Diseases
- Schizophrenia
- NCT number
- NCT07434401
What you commit to
- Study type: Observational
- Participants enrolled: 93
- From 1 May 2025 to the primary completion date, 31 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- For Methamphetamine Use Disorder (MUD) Group:
- \*Inclusion Criteria:
- Diagnosis of MUD according to DSM-5-TR
- Medication-free for at least one month prior to admission
- Age ≥ 18 years and \<65 years
- Provided informed consent
- For Methamphetamine Use Disorder (MUD) Group:
- \*Exclusion Criteria:
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than MUD
- Alcohol use disorder
- For Methamphetamine-Induced Psychotic Disorder (MP) Group:
- \*Inclusion Criteria:
- Diagnosis of MP according to DSM-5-TR
- Medication-free for at least one month prior to admission
- Age ≥ 18 years and \<65 years
- Provided informed consent
- For Methamphetamine-Induced Psychotic Disorder (MP) Group:
- \*Exclusion Criteria:
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than MP
- Alcohol use disorder
- For Healthy Control Group:
- \*Inclusion Criteria:
- No psychiatric diagnosis
- No systemic or immunological illness
- Medication-free for at least one month
- Age ≥ 18 years and \< 65 years
- Provided informed consent
- For Healthy Control Group:
- \*Exclusion Criteria:
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than schizophrenia
- Alcohol/drug/substance use
Age in the registry: 18 years to 65 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Elazığ Mental Health and Diseases Hospital Coordinator of this site? Confirm its status | Elâzığ | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.